Subcutaneous Female infertility Adult: Dose should be individualised. Recommended initial dose: 75 IU/day; may increase dose by up to 37.5 IU after 14 days; further increases of the same magnitude can be made, if needed, every 7 days. Max: 300 IU/day. If response is appropriate, hCG (5,000 USP IU) is given 1 day after the last dose. Withhold hCG if serum estradiol is >2000 pg/ml, if the ovaries are abnormally enlarged or if abdominal pain occurs. Generally, therapy should not exceed 35 days. Assisted reproductive technologies Adult: Initially, 150-225 IU/day for at least 4 days, to be started in the...
... Show more
Contraindication
Hypersensitivity. Abnormal genital bleeding of undetermined origin, sex hormone sensitive malignancies of the reproductive tract and accessory organs, an organic intracranial lesion e.g. pituitary tumor, ovarian cysts or enlargement of undetermined origin, high levels of FSH indicating primary gonadal failure, uncontrolled thyroid or adrenal dysfunction, pregnancy, lactation.
Mode of Action
Follitropin alfa is a human FSH preparation of recombinant DNA origin. It stimulates ovarian follicular growth in women who do not have primary ovarian failure and stimulates spermatogenesis in men with hypogonadotrophic hypogonadism.
Precaution
May result in multiple births. Ovarian hyperstimulation syndrome, serious pulmonary conditions and thromboembolic events may occur. Evaluate patients for hypothyroidism, adrenocortical deficiency, hyperprolactinaemia, pituitary and hypothalamic tumors before starting therapy.
Lactation: Excretion in milk unknown; not recommended
Side Effect
Ovarian cysts, mild to severe Inj site reactions, headache, mild to moderate ovarian hyperstimulation syndrome (OHSS), abdominal pain, GI disturbances.
Rarely, severe OHSS, ovarian torsion, thromboembolism, mild systemic allergic reactions.
Pregnancy Category Note
Pregnancy
Contraindicated
Lactation
Unknown if excreted in breast milk
Interaction
Other ovulation stimulating agents (eg hCG, clomiphene citrate) may potentiate the follicular response, concurrent use of GnRH agonist-induced pituitary desensitisation may increase the dosage of Gonal-f needed to elicit an adequate ovarian response.
ব্যবসার জন্য পাইকারি দামে পণ্য কিনতে রেজিস্টেশন করুন
The information provided herein is accurate, updated and complete as per the best practices of the Company. Please note that this information should not be treated as a replacement for physical medical consultation or advice. We do not guarantee the accuracy and the completeness of the information so provided. The absence of any information and/or warning to any drug shall not be considered and assumed as an implied assurance of the Company. We do not take any responsibility for the consequences arising out of the aforementioned information and strongly recommend you for a physical consultation in case of any queries or doubts.